PredictImmune invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit


PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, announced today that it has been invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit, taking place in Newark, NJ, USA on 17th and 18th October 2018.

PredictImmune CSO, Eoin McKinney to lead discussion on fluid biomarkers

The two-day invitation-only participatory event will feature presentations and breakout sessions from leading IBD key opinion leaders, including key stakeholders from academia, industry, foundations and regulatory bodies. The Summit is sponsored in part by AbbVie, Arena Pharmaceuticals, Inc and Janssen Biotech, Inc.

Discussions will focus on the distinct needs in the context of early-stage clinical studies, later-stage trials and clinical practice, as well as opportunities to address biomarker needs for IBD drug development through emerging technologies such as transcriptomics and big data analysis.

Dr Eoin McKinney, CSO PredictImmune, will lead a discussion on the second day of the event, focusing on fluid biomarkers. Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.

PredictImmune’s first product, addressing IBD (both Crohn's disease and ulcerative colitis), is a test based on a simple whole-blood quantitative PCR assay and predicts long-term disease outcome at diagnosis prior to treatment. This allows patients to be grouped into those likely to follow either a more dormant or frequently relapsing disease course and thereby informs clinical management. The R&D phase of the test has been completed and the test is currently in the final stages of validation ahead of product launch.

For more information please visit


Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Research Campus Ltd.